Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the ...

According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 ...

The next chapter in hematology is being written at City of Hope. For patients navigating blood cancers like leukemia, lymphoma or multiple myeloma, having access to specialized experts and the most ...

DelveInsight's BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

A recent review concluded that artificial intelligence (AI) is rapidly transforming the diagnosis and treatment of haematological malignancies by enhancing diagnostic accuracy and ...

Lenalidomide is an oral immunomodulatory agent widely used in the treatment of multiple myeloma, mantle cell lymphoma, and non-Hodgkins Lymphoma. The launch of Accord's Lenalidomide Capsules provides ...

Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant ...